Entacapone
- Generic Name
- Entacapone
- Brand Names
- Comtan, Comtess, Stalevo, Entacapone Orion, Entacapone Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H15N3O5
- CAS Number
- 130929-57-6
- Unique Ingredient Identifier
- 4975G9NM6T
- Background
Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the...
- Indication
Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".
- Associated Conditions
- Parkinson's Disease (PD), Wearing Off Effect
- Associated Therapies
- -
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
- Conditions
- Interventions
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2014-07-17
- Target Recruit Count
- 14
- Registration Number
- NCT00547911
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
COMT Polymorphism and Entacapone Efficacy
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2010-04-29
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 60
- Registration Number
- NCT00373087
- Locations
- 🇫🇷
Centre d'Investigation Clinique, Hôpital de la Pitié-Salpétrière,, Paris, France
Treatment of Orthostatic Intolerance
- Conditions
- Interventions
- Drug: AtomoxetineDrug: AcetazolamideDietary Supplement: MelatoninOther: NO DrugDrug: Isosorbide DinitrateRadiation: PlaceboDevice: Breathing DeviceOther: Drinking WaterProcedure: IV SalineDevice: Abdominal binderDrug: IndomethacinDrug: MidodrineDrug: MecamylamineDrug: ClonidineDrug: EntacaponeDrug: memantineDrug: ModafinilDrug: OctreotideDrug: SertralineDrug: Atomoxetine & PropranololDrug: Entacapone & PropranololDrug: PropranololDrug: Modafinil & Propranolol
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Satish R. Raj
- Target Recruit Count
- 150
- Registration Number
- NCT00262470
- Locations
- 🇺🇸
Vanderbilt University Autonomic Dysfunction Center, Nashville, Tennessee, United States
An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 285
- Registration Number
- NCT00237263
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Entacapone Augmentation for Schizophrenia
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 52
- Registration Number
- NCT00192855
- Locations
- 🇮🇱
Rambam medical center, Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.